Full Press Release Details
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
CAMBRIDGE, Mass., September 24, 2024 /PRNewswire/ -- NeuroSense
Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases,
today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained
compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.
To regain compliance with the Rule, the Company's ordinary shares
were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved
on September 20, 2024. Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed.
NeuroSense's CEO, Alon Ben-Noon said, " We are pleased to
have regained compliance with Nasdaq's minimum bid price requirement, an important step that reflects our commitment to advancing PrimeC.
With the positive momentum following our Phase 2b trial results, we are looking forward to initiating the Phase 3 trial in the US and
continuing our discussions with potential partners."
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from
debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS),
Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with
limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on
strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple
pathways associated with these diseases.
be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements"
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as "anticipate," "believe," "contemplate," "could," "estimate," "expect,"
"intend," "seek," "may," "might," "plan," "potential," "predict,"
"project," "target," "aim," "should," "will" "would," or the negative of these
words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based
on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to
predict and include statements regarding initiating the Phase 3 trial for PrimeC in the US. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual
results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include
unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial or a delay
in initiating the Phase 3 trial for PrimeC in the US, the timing of expected regulatory and business milestones, risks associated with
meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such
meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding
outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of
any product candidates of NeuroSense; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange
Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and
uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with
the Securities and Exchange Commission on March 22, 2023. Forward-looking statements contained in this announcement are made as of this
date, and NeuroSense undertakes no duty to update such information except as required under applicable law.